畅销原因：2024年2月16日，FDA批准奥马珠单抗用于减少成人和一岁及以上食物过敏儿童因意外接触食物而导致的过敏反应。临床试验表明，接受 ...

近期，康诺亚-B（02162.HK）的股价再度下滑，单日下跌超过5%，自12月21日至今，该股票的整体跌幅已超过30%。截至发稿，康诺亚股价报27.75港元，成交额达1861万港元。这一显著下跌引发了投资者的广泛关注，而导致此次股价疲软的主要原因与公司在国家医保目录谈判中关于杜匹鲁单抗（Dupixent）的降价决策密切相关。

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

在其他近期新闻中，Regeneron Pharmaceuticals报告其旗舰眼科药物Eylea的高剂量销售低于预期，导致股价下跌。2024年第四季度的销售额显著低于分析师预期，该药物在美国的净产品销售额为3.05亿美元，而估计为4.57亿美元。摩根大通的Chris Schott维持对Regeneron的增持评级，评论称Eylea HD销售实际上已经趋于平稳。

Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...

根据InvestingPro数据，11位分析师最近上调了他们的盈利预期。这种乐观情绪源于Kymera的KT-621的潜力，这是一种靶向蛋白降解（TPD）药物，正在开发为治疗Th2介导疾病的口服疗法。

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...

智通财经APP获悉，康诺亚-B (02162)再跌超5%，12月21日至今累计跌幅已超30%，截至发稿，跌4.31%，报27.75港元，成交额1861万港元。 花旗此前发布研究报告称，近期康诺亚股价的疲弱已充分反映了其在国家医保目录谈判中，杜匹鲁单抗 ...